Ertugliflozin meets in Phase III diabetes studies

Merck & Co. Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) said diabetes candidate ertugliflozin ( PF-4971729, MK-8835) met the primary endpoints in two Phase III studies. The partners plan to submit an NDA for the oral sodium-glucose cotransporter 2 (

Read the full 398 word article

How to gain access

Continue reading with a
two-week free trial.